glaxosmithkline enters into further agreement

GlaxoSmithKline enters into further Agreement with OBJ
OBJ Limited (ASX: OBJ) is pleased to announce the signing of an Evaluation Agreement
with GlaxoSmithKline Consumer Healthcare (GSK). GSK has granted permission to the
Company to release the following statement:
?gOBJ Limited wishes to advise that it has entered into a short term evaluation
agreement with GlaxoSmithKline Consumer Healthcare (GSK).
The Evaluation Agreement involves an evaluation of OBJ?fs ETP technology in a
non?]prescription consumer healthcare application.
OBJ and GSK have worked together on three previous occasions and the current
Agreement is a continuation of that relationship.?h
Background
GlaxoSmithKline is the world's second largest pharmaceutical and consumer healthcare
company with products ranging from vaccines and oncology products through to overthe?]
counter medicines and nutritional products.
OBJ first collaborated with GSK in 2006 in an advanced delivery program employing the
Company?fs Dermaportation technology. This program was further expanded to involve
both the Company?fs Dermaportation and ETP technologies. This relationship was
announced to shareholders in May 2007 following approval of that release by GSK. A
further confidential collaboration with GSK was undertaken in 2008 in an undisclosed
consumer healthcare field and the current announcement continues the work in that
same commercial field.
The results, application field and drug used in the current program are, by agreement,
to remain confidential.